Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

Semaglutide Nears Market For Obesity

 
• By John Davis
  
Nyhavn in Copenhagen
Copenhagen, where Novo Nordisk is headquartered • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas